ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2016-09-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-15-1002PMID 27638859
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Profile of veliparib and its potential in the treatment of solid tumors

  2015cited by this paper
• Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

  2015cited by this paper
• Targeting DNA damage response in cancer therapy

  2014cited by this paper
• ATM signalling and cancer

  2014cited by this paper
• Ataxia‐telangiectasia‐mutated protein expression with microsatellite instability in gastric cancer as prognostic marker

  2014cited by this paper
• ATM Regulates Insulin-Like Growth Factor 1-Secretory Clusterin (IGF-1-sCLU) Expression that Protects Cells against Senescence

  2014cited by this paper
• PARP inhibitors for anticancer therapy.

  2014cited by this paper
• Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

  2014cited by this paper
• The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

  2013cited by this paper
• Biological consequences of radiation-induced DNA damage: relevance to radiotherapy.

  2013cited by this paper
• ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

  2013cited by this paper
• Topoisomerase I poisoning results in PARP-mediated replication fork reversal

  2012cited by this paper
• Recurrent R-spondin fusions in colon cancer

  2012influential reference
• The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

  2012cited by this paper
• The role of ATM and 53BP1 as predictive markers in cervical cancer

  2012cited by this paper
• Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

  2012cited by this paper
• The intersection between DNA damage response and cell death pathways.

  2012cited by this paper
• Harnessing synthetic lethal interactions in anticancer drug discovery

  2011cited by this paper
• ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance

  2011cited by this paper
• PARP inhibitor treatment in ovarian and breast cancer.

  2011cited by this paper
• Synthetic lethality: exploiting the addiction of cancer to DNA repair.

  2011cited by this paper
• A public genome-scale lentiviral expression library of human ORFs

  2011cited by this paper
• HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

  2011cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks

  2008cited by this paper
• Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats

  2007cited by this paper
• p53 targets identified by protein expression profiling

  2007cited by this paper
• Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

  2007cited by this paper
• ATM Activation and DNA Damage Response

  2007cited by this paper
• Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition

  2007cited by this paper
• The Intricacies of p21 Phosphorylation: Protein/Protein Interactions, Subcellular Localization and Stability

  2006cited by this paper
• Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma

  2006cited by this paper
• The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks

  2005cited by this paper
• Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy.

  2004cited by this paper
• DNA damage checkpoint control in cells exposed to ionizing radiation

  2003cited by this paper
• Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.

  2003cited by this paper
• A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients.

  2003cited by this paper
• Polymorphisms in DNA repair genes and associations with cancer risk.

  2002cited by this paper
• PUMA, a novel proapoptotic gene, is induced by p53.

  2001cited by this paper
• Characterization of ATM expression, localization, and associated DNA-dependent protein kinase activity.

  1998cited by this paper

• Clinical approaches to overcome PARP inhibitor resistance

  2025cites this paper
• Ataxia-Telangiectasia Mutated (ATM) gene signaling pathways in human cancers and their therapeutic implications.

  2024cites this paper
• Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency

  2024cites this paper
• Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

  2023cites this paper
• Mapping combinatorial drug effects to DNA damage response kinase inhibitors

  2023cites this paper
• Network analysis reveals that the tumor suppressor lncRNA GAS5 acts as a double-edged sword in response to DNA damage in gastric cancer

  2022cites this paper
• Prospects of circular RNAs: the regulators of drug resistance and metastasis in gastric cancer.

  2022cites this paper
• DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive Review

  2022cites this paper
• MTFR2, A Potential Biomarker for Prognosis and Immune Infiltrates, Promotes Progression of Gastric Cancer Based on Bioinformatics Analysis and Experiments

  2021cites this paper
• Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR

  2021cites this paper
• A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer

  2021cites this paper
• Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  2021cites this paper
• The CINs of Polo-Like Kinase 1 in Cancer

  2020cites this paper
• Hsa_circ_0001546 acts as a miRNA-421 sponge to inhibit the chemoresistance of gastric cancer cells via ATM/Chk2/p53-dependent pathway.

  2020cites this paper
• Irinotecan Induces Autophagy-Dependent Apoptosis and Positively Regulates ROS-Related JNK- and P38-MAPK Pathways in Gastric Cancer Cells

  2020cites this paper
• Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer

  2020cites this paper
• A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

  2020cites this paper
• Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors

  2020cites this paper
• Apatinib regulates the growth of gastric cancer cells by modulating apoptosis and autophagy

  2020cites this paper
• OTT_A_240803 2807..2817

  2020cites this paper
• Cannabidiol Induces Cell Cycle Arrest and Cell Apoptosis in Human Gastric Cancer SGC-7901 Cells

  2019cites this paper
• PDRG1 gene silencing contributes to inhibit the growth and induce apoptosis of gastric cancer cells.

  2019cites this paper
• BDE-209 induces male reproductive toxicity via cell cycle arrest and apoptosis mediated by DNA damage response signaling pathways.

  2019cites this paper
• ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer

  2018cites this paper
• Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary.

  2018cites this paper
• Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer

  2018cites this paper
• Biomarkers for Homologous Recombination Deficiency in Cancer

  2018cites this paper
• In Vivo and In Vitro Effects of ATM/ATR Signaling Pathway on Proliferation, Apoptosis, and Radiosensitivity of Nasopharyngeal Carcinoma Cells

  2017cites this paper
• Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.

  2017cites this paper
• Customized Chemotherapy in Advanced Gastric Cancer

  2017cites this paper
• BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.

  2017cites this paper
• Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.

  2017cites this paper
• Review Review of recent molecular landscape knowledge of gastric cancer

  year unknowncites this paper